PMID- 24565079
OWN - NLM
STAT- MEDLINE
DCOM- 20150414
LR  - 20181202
IS  - 1469-5111 (Electronic)
IS  - 1461-1457 (Linking)
VI  - 17
IP  - 8
DP  - 2014 Aug
TI  - Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome.
PG  - 1139-48
LID - 10.1017/S1461145714000157 [doi]
AB  - Second-generation antipsychotics (SGAs) are commonly used to treat schizophrenia. 
      However, SGAs cause metabolic disturbances that can manifest as metabolic 
      syndrome (MetS) in a subset of patients. The causes for these metabolic 
      disturbances remain unclear. We performed a comprehensive metabolomic profiling 
      of 60 schizophrenia patients undergoing treatment with SGAs that puts them at 
      high (clozapine, olanzapine), medium (quetiapine, risperidone), or low 
      (ziprasidone, aripiprazole) risk for developing MetS, compared to a cohort of 20 
      healthy controls. Multiplex immunoassays were used to measure 13 metabolic 
      hormones and adipokines in plasma. Mass spectrometry was used to determine levels 
      of lipids and polar metabolites in 29 patients and 10 controls. We found that 
      levels of insulin and tumor necrosis factor alpha (TNF-alpha) were significantly 
      higher (p < 0.005) in patients at medium and high risk for MetS, compared to 
      controls. These molecules are known to be increased in individuals with high body 
      fat content and obesity. On the other hand, adiponectin, a molecule responsible 
      for control of food intake and body weight, was significantly decreased in 
      patients at medium and high risk for MetS (p < 0.005). Further, levels of 
      dyacylglycerides (DG), tryacylglycerides (TG) and cholestenone were increased, 
      whereas alpha-Ketoglutarate and malate, important mediators of the tricarboxylic acid 
      (TCA) cycle, were significantly decreased in patients compared to controls. Our 
      studies suggest that high- and medium-risk SGAs are associated with disruption of 
      energy metabolism pathways. These findings may shed light on the molecular 
      underpinnings of antipsychotic-induced MetS and aid in design of novel 
      therapeutic approaches to reduce the side effects associated with these drugs.
FAU - Paredes, R Madelaine
AU  - Paredes RM
AD  - Department of Psychiatry,University of Texas Health Science Center San 
      Antonio,San Antonio, TX,USA.
FAU - Quinones, Marlon
AU  - Quinones M
AD  - Department of Psychiatry,University of Texas Health Science Center San 
      Antonio,San Antonio, TX,USA.
FAU - Marballi, Ketan
AU  - Marballi K
AD  - Department of Cellular and Structural Biology,University of Texas Health Science 
      Center San Antonio,San Antonio, TX,USA.
FAU - Gao, Xiaoli
AU  - Gao X
AD  - Department of Biochemistry,University of Texas Health Science Center San 
      Antonio,San Antonio, TX,USA.
FAU - Valdez, Celina
AU  - Valdez C
AD  - Department of Psychiatry,University of Texas Health Science Center San 
      Antonio,San Antonio, TX,USA.
FAU - Ahuja, Seema S
AU  - Ahuja SS
AD  - Department of Medicine,University of Texas Health Science Center San Antonio,San 
      Antonio, TX,USA.
FAU - Velligan, Dawn
AU  - Velligan D
AD  - Department of Psychiatry,University of Texas Health Science Center San 
      Antonio,San Antonio, TX,USA.
FAU - Walss-Bass, Consuelo
AU  - Walss-Bass C
AD  - Department of Psychiatry,University of Texas Health Science Center San 
      Antonio,San Antonio, TX,USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20140225
PL  - England
TA  - Int J Neuropsychopharmacol
JT  - The international journal of neuropsychopharmacology
JID - 9815893
RN  - 0 (Adiponectin)
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Cholestenones)
RN  - 0 (Diglycerides)
RN  - 0 (Insulin)
RN  - 0 (Ketoglutaric Acids)
RN  - 0 (Malates)
RN  - 0 (Triglycerides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 817L1N4CKP (malic acid)
SB  - IM
MH  - Adiponectin/blood
MH  - Adult
MH  - Antipsychotic Agents/*adverse effects
MH  - Case-Control Studies
MH  - Cholestenones/blood
MH  - Diglycerides/blood
MH  - Female
MH  - Humans
MH  - Insulin/blood
MH  - Ketoglutaric Acids/blood
MH  - Malates/blood
MH  - Male
MH  - Metabolic Syndrome/blood/complications/*metabolism
MH  - *Metabolomics
MH  - Schizophrenia/blood/complications/drug therapy/*metabolism
MH  - Triglycerides/blood
MH  - Tumor Necrosis Factor-alpha/blood
MH  - Young Adult
EDAT- 2014/02/26 06:00
MHDA- 2015/04/15 06:00
CRDT- 2014/02/26 06:00
PHST- 2014/02/26 06:00 [entrez]
PHST- 2014/02/26 06:00 [pubmed]
PHST- 2015/04/15 06:00 [medline]
AID - S1461145714000157 [pii]
AID - 10.1017/S1461145714000157 [doi]
PST - ppublish
SO  - Int J Neuropsychopharmacol. 2014 Aug;17(8):1139-48. doi: 
      10.1017/S1461145714000157. Epub 2014 Feb 25.